Meeting
2023 ASCO Annual Meeting
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
Authors
Prantesh Jain
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Prantesh Jain , Alan Hutson , Cayla Janes , Debora S. Bruno , Greg Andrew Durm , Ashish Sangal , Bhoomi Mehrotra , Tania Crombet Ramos , Kalet Leon , Grace K. Dy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT02955290
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS2677)
DOI
10.1200/JCO.2023.41.16_suppl.TPS2677
Abstract #
TPS2677
Poster Bd #
512a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
First Author: Rachel Frascati
Poster
2022 ASCO Annual Meeting
PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.
First Author: Giuseppe Lo Russo
Poster
2022 ASCO Annual Meeting
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.
First Author: Marina Chiara Garassino
Poster
2022 ASCO Annual Meeting
Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
First Author: Si-Yang Maggie Liu